Episode 426: ASCO 2025 - AMPLITUDE Phase 3 of PARPi in mHSPC

By The Uromigos - Last Updated: June 9, 2025

Dr. Gerhardt Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025, including the history of PARP inhibitor use for prostate cancer.

Post Tags:Uromigos-ASCO

Related Podcasts

Episode 425: ASCO 2025 - AI-Enabled Selection of Patients for Benefit of ADT + ARPI
Uromigos-ASCO
Episode 424: ASCO 2025 - Emergency Podcast on the Prostate Rapid Oral Session
Uromigos-ASCO
Episode 423: ASCO 2025 - Casdatifan Plus Cabozantinib in Refractory RCC
Uromigos-ASCO
Episode 422: ACSO 2025 - ctDNA Data From NIAGARA
Uromigos-ASCO
Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer
Uromigos-ASCO
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |